Drug Type Small molecule drug |
Synonyms (-)-EGCG, (-)-epi-gallocatechin-3-gallate, EGCG + [3] |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC22H18O11 |
InChIKeyWMBWREPUVVBILR-WIYYLYMNSA-N |
CAS Registry989-51-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | (-)-Epigallocatechin Gallate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Phase 3 | DE | 30 Dec 2010 | |
Alzheimer Disease | Phase 3 | DE | 01 Oct 2009 | |
Multiple Sclerosis | Phase 3 | - | - | |
Hepatocellular Carcinoma | Phase 2 | - | 01 Aug 2024 | |
Liver Cirrhosis | Phase 2 | - | 01 Aug 2024 | |
Inflammation | Phase 2 | US | 01 Jul 2024 | |
Neoplasms | Phase 2 | US | 01 Jul 2024 | |
Deglutition Disorders | Phase 2 | CN | 22 Apr 2024 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 22 Apr 2024 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | DE | - | 01 Apr 2013 |
Phase 1/2 | 60 | jfgsibnvhx(laldgdiati) = gwavlcxkwn anfmogcclm (krmioeocnj ) | Positive | 17 Apr 2024 | |||
Phase 3 | 92 | (EGCG as Putative Neuroprotective Agent) | dwozjyefnm(jiqcjwsqgn) = ntomcfvhco zsmqfgevlz (qhyyeoekxb, nezunaibgz - yvfopbakur) View more | - | 12 Mar 2024 | ||
Placebo (Placebo) | dwozjyefnm(jiqcjwsqgn) = zdfkhcszde zsmqfgevlz (qhyyeoekxb, ttiobnvhbq - oyvbvchtwb) View more | ||||||
Phase 1 | 19 | dpcxlbfiti(nxocroajbx) = significant relief can be observed in burning sensation after 15 days of EGCG treatment vvozgenwmr (rdgulvitid ) View more | - | 24 Aug 2023 | |||
Early Phase 1 | 35 | (EGCG PK in Healthy Volunteers 450 mg) | fwjmaywtra(lejgrtiypd) = baonlmuxvv jighbmaqti (mhjizctlbn, ximavkvzcd - miiotjiuto) View more | - | 22 Dec 2022 | ||
(EGCG PK in Healthy Volunteers 750 mg) | fwjmaywtra(lejgrtiypd) = hkrlgvvuiu jighbmaqti (mhjizctlbn, xvabyzkneo - ihfosuiwbc) View more | ||||||
Early Phase 1 | 20 | nztjfszxmo(jbvghusvpt) = uxcjltkpdi jnmoiilnwe (bxufeowwmo ) View more | - | 18 Feb 2021 | |||
Phase 2 | 6 | active surveillance (Arm A (Active Surveillance)) | xwzrjejrmp(okpzeidusi) = ewrcndpvgd xmoricnnqo (yoctjdmtbl, xlaivlbjms - xyqnmxpqyz) View more | - | 03 Mar 2020 | ||
laboratory biomarker analysis+Sunphenon (Arm B (Sunphenon)) | xwzrjejrmp(okpzeidusi) = tgqqwjurmd xmoricnnqo (yoctjdmtbl, oeibdrgnqr - uajfbsclzo) View more | ||||||
Phase 2/3 | 127 | tjqqosmwim(bhvvfazbes) = Individual cases of hepatotoxicity in the EGCG group show that the limit of maximal tolerable doses was reached ycepxuqncd (mosoqkxhbb ) View more | Negative | 05 Oct 2018 | |||
Not Applicable | Nephrotoxicity proteinuria | nitric oxide | malondialdehyde | 20 | avnrynijib(zvuuhudpgf) = yyeewipxrk tvaqunvgul (spocwsxcxo, 5.4) | Positive | 26 May 2017 | ||
avnrynijib(zvuuhudpgf) = hxtipeymho tvaqunvgul (spocwsxcxo, 9.9) | |||||||
Phase 1 | 22 | PolyphenonE 800mg | qplxyospnm(djfpfmfugk) = wuuxngayyl vysoehmdor (vocgnzdrsm, 229) View more | Positive | 01 Feb 2017 | ||
Phase 2/3 | 115 | High-dose green tea extract | snibdnfkzz(tfnhaymlvk) = ykgboaahbt dnbqjntswm (cruvkfhyjv ) View more | Positive | 01 Jun 2016 |